<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=192888919167017&amp;ev=PageView&amp;noscript=1">
Tuesday,  April 23 , 2024

Linkedin Pinterest
News / Health / Health Wire

Democratic senator asks drugmakers about opioid sales plans

By KEVIN FREKING, Associated Press
Published: March 28, 2017, 9:15am

WASHINGTON — A Democratic senator is seeking marketing information, sales records and studies from manufacturers of the top-selling opioid products in the United States to determine whether drugmakers have contributed to an overuse of the pain killers.

Sen. Claire McCaskill of Missouri said that sales of prescription opioids have quadrupled since 1999, taking a financial toll on the government and a deadly toll on thousands of consumers.

McCaskill said previous government and media reports show an industry not focused on preventing abuse but on fostering addiction. She is investigating whether such practices continue today.

Some of the records she is asking for from the five companies include the sales rep expenses for entertaining physicians, payments made to health care advocacy groups, as well as marketing and business plans.

“We have an obligation to everyone devastated by this epidemic to find answers,” McCaskill said in a prepared statement issued Tuesday. “All of this didn’t happen overnight. It happened one prescription and marketing program at a time.”

More than 52,000 people died of a drug overdose in 2015, and roughly two-thirds of them had used prescription opioids like OxyContin or Vicodin or illegal drugs like heroin, according to the Centers for Disease Control and Prevention. Those overdoses have jumped 33 percent in the past five years alone, with some states reporting the death toll had doubled or more.

Congress worked on a bipartisan basis last year in a bid to boost funding for treatment programs. McCaskill is the ranking Democratic lawmaker on the Senate Committee on Homeland Security and Governmental Affairs. The Republican chairman, Sen. Ron Johnson, did not sign the letter seeking the information from the drug manufacturers, but was sent copies of her letters.

Loading...